You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a Urine Test for At-Home Monitoring of Blood Phe Levels for PKU
SBC: CIRCA BIOSCIENCE LLC Topic: NICHDPROJECT SUMMARY/ABSTRACT This project proposes the development of technologies to provide low-cost monitoring of phenylalanine (Phe) levels in the blood by a simple, noninvasive, at-home urine test, in order to enable daily monitoring by individuals with phenylketonuria (PKU). Also known as phenylalanine hydroxylase deficiency, PKU is a rare inborn error of metabolism that occurs in the US at a fr ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis
SBC: GLYCOPATH INC Topic: 400Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Programming Metabolically Fit TILs for Immunotherapy
SBC: LIPO-IMMUNO TECH LLC Topic: NCIABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Using Interactive Digital Media to Teach Cardiopulmonary Resuscitation to High School Students
SBC: CORAM TECHNOLOGIES, INC. Topic: 500Abstract Out-of-hospital cardiac arrest affects over 350,000 people in the U.S. annually, but only 10.8% survive. Bystander cardiopulmonary resuscitation (CPR) improves survival, but rates of training in the U.S. are low. It is recently required by law in 39 U.S. states that high school students learn CPR. However, current methods of teaching CPR use outdated pedagogical strategies and expensive d ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Large Form Factor Scintillators for Nuclear Battlefield Operations
SBC: N.P. PHOTONICS, INC. Topic: DTRA22D002The current state-of-the-art radiation detection materials have different drawbacks limiting their applications in the next-generation mobile radiation detection system. NP Photonics proposes to develop a novel scintillating glass that can be used to make large form-factor scintillators for nuclear battlefield operations. The proposed scintillating glass has the advantages of low cost, short decay ...
STTR Phase I 2023 Department of DefenseDefense Threat Reduction Agency -
3D microprinting-enabled microinjection needle arrays for enhanced therapeutics delivery into the brain
SBC: SEETRUE TECHNOLOGY, LLC Topic: 101PROJECT SUMMARY Microinjection technologies underlie many research and clinical applications that require gene and cell delivery, including studies and emerging treatments of neurological conditions (e.g., neurodegenerative diseases, traumatic brain injury, and cancer). Unfortunately, challenges associated with the microinjection tools by which the viral vectors and cells inherent in these applica ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inducible HMGB1 antagonist for viral-induced acute lung injury.
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NHLBIFor more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
SBC: FibroBiologics, LLC Topic: NHLBIIdiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus
SBC: Epifocus LLC Topic: 104The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An immunotherapeutic IgY formulation against norovirus diarrhea
SBC: SCALED MICROBIOMICS LLC Topic: NIAIDProject Summary/Abstract for STTR Phase I Application: An immunotherapeutic IgY formulation against norovirus diarrhea Human norovirus (HuNoV) infects millions of people globally each year, causing diarrheal illness resulting in more than 200,000 deaths annually, particularly in the very young, the very old, and the immunocompromised. There is currently neither an effective vaccine nor effective t ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health